The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.

Khosravan, Reza; Grabowski, Brian A; Mayer, Michael D; Wu, Jing-Tao; Joseph-Ridge, Nancy; Vernillet, Laurent

Khosravan, Reza; Grabowski, Brian A; Mayer, Michael D; Wu, Jing-Tao; Joseph-Ridge, Nancy; Vernillet, Laurent.

Affiliation

Khosravan R; Department of Drug Metabolism and Pharmacokinetics, TAP Pharmaceutical Products Inc, 675 North Field Drive, Lake Forest, IL 60045, USA.

J Clin Pharmacol ; 46(1): 88-102, 2006 Jan.

Article in En | MEDLINE | ID: mdl-16397288

Subject(s)

Liver Diseases/metabolism; Thiazoles/pharmacokinetics; Administration, Oral; Adult; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors/administration & dosage; Enzyme Inhibitors/pharmacokinetics; Febuxostat; Female; Humans; Male; Middle Aged; Thiazoles/administration & dosage; Xanthine Oxidase/antagonists & inhibitors

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Thiazoles / Liver Diseases Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2006 Type: Article

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Thiazoles / Liver Diseases Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2006 Type: Article